High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy

Thrombosis and Haemostasis

Volumn 90, Issue 6, 2003, Pages 1163-1172

  Vene, Nina ^a   Mavri, Alenka ^a   Košmelj, Katarina ^b   Stegnar, Mojca ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Atrial fibrillation; Coagulation; Fibrinolysis; Oral anticoagulant therapy

Indexed keywords

ANTICOAGULANT AGENT; ANTIGEN; D DIMER; MARKER; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; PROTHROMBIN FRAGMENT 1 PLUS 2; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGE; AGED; ANAMNESIS; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE MARKER; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEMOSTASIS; HUMAN; HYPERTENSION; INTERNATIONAL STANDARD UNIT; INTRACARDIAC THROMBOSIS; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REFERENCE VALUE; STROKE; SYSTOLE; VASCULAR DISEASE;

EID: 0346272855     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-06-0363     Document Type: Article

References (38)

1. Cerebral Embolism Task Force. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol 1989; 46: 727-43.
2. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and acute coronary syndromes. (First of two parts). N Engl J Med 1992; 326: 242-50.
3. Asakura H, Hifumi S, Jokaji H, et al. Prothrombin fragment F1+2 and thrombin-antithrombin III complex are useful markers of hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinol 1992; 3: 469-73.
4. Kumagai K, Fukunami M, Ohmori M, et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990; 16: 377-80.
5. Lip GYH, Lowe GDO, Rumley A, et al. Increased markers of thrombogenesis in chronic atrial fibrillation: Effects of warfarin treatment. Br Heart J 1995; 73: 527-33.
6. Kahn SR, Solymoss S, Flegel KM. Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation. Can Med Assoc J 1997; 157: 685-9.
7. Roldan V, Marin F, Marco P, et al. Hypofibrinolysis in atrial fibrillation. Am Heart J 1998; 136: 956-60.
8. Fowkers FGR, Lowe GDO, Housley E, et al. Cross-linked fibrin degradation products, progression of peripheral disease, and risk of coronary heart disease. Lancet 1993; 342: 84-6.
9. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease. Prospective study and meta-analysis. Circulation 2001; 103: 2323-7.
10. Ridker PM, Hennekens CH, Cerskus A, et al. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-40.
11. Lowe GDO, Yarnell JWG, Sweetnam PM, et al. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and risk of major ischemic heart disease in the Caerphilly study. Thromb Haemost 1998; 79: 129-33.
12. Thompson SG, Kienast J, Pyke SDM, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
13. Ridker PM, Hennekens CH, Stampfer MJ, et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-3.
14. Cushman M, Folsom AR, Wang L, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 2003; 101: 1243-8.
15. Palareti G, Legnanai C, Cosmi B, et al. Risk of venous thromboembolism recurrence: High negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87: 7-12.
16. Feinberg WM, Pearce LA, Hart RG, et al. for the Stroke Prevention in Atrial Fibrillation investigators. Markers of thrombin and platelet activity in patients with atrial fibrillation: Correlation with stroke among 1531 participants in the Stroke Prevention in Atrial Fibrillation III Study. Stroke 1999; 30: 2547-53.
17. Bruhn HD, Conard J, Mannucci M, Monteagudo J, Pelzer H, Reverter JC, et al. Multicentric evaluation of a new assay for prothrombin fragment F1+2 determination. Thromb Haemost 1992; 68: 413-7.
18. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50.
19. Giansante C, Fiotti N, Calabrese S, et al. D-dimer and anticoagulation in patients with mechanical prostetic heart valves. A 2 year follow up. Arterioscler Thromb Vasc Biol 1997; 17: 1320-4.
20. Fattorini A, Crippa L, Vigano' D'Angelo S, et al. Risk of deep vein thrombosis recurrence: High negative predictive value of D-dimer performed during oral anticoagulation. Thromb Haemost 2002; 88: 162-3.
21. Stegnar M, Mavri A. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects. Thromb Haemost 1995; 73: 453-7.
22. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Circulation 1994; 90: 583-612.
23. The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
24. Van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation. An individual patient meta-analysis. JAMA 2002; 288: 2441-8.
25. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-6.
26. Kistler JP, Singer DE, Millenson MM, et al. Effect of low intensity warfarin anticoagulation on level of activity of hemostatic system in patients with atrial fibrillation. Stroke 1993; 42: 1360-5.
27. Lip GYH, Lip PL, Zarifis J, et al. Fibrin D-dimer and β thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Circulation 1996; 94: 425-31.
28. Koefoed BG, Fedderson C, Gulløv AL, et al. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1+2 in patients with atrial fibrillation. Thromb Haemost 1997; 77: 845-8.
29. Li Saw Hee FL, Blann AD, et al. Effects of fixed low dose warfarin, aspirin-warfarin combination therapy and dose adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000; 31: 828-33.
30. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8.
31. Ardissino D, Merlini PA, Barberis P, et al. Thrombin activity and early outcome in unstable angina pectoris. Circulation 1996; 93: 1634-9.
32. Mahé I, Drouet L, Chassany O, et al. D-dimer: A characteristic of the coagulation state of each patient with chronic atrial fibrillation. Throm Res 2002; 107: 1-6.
33. Lip GYH, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow triade revisited. J Am Coll Cardiol 1999; 33: 1424-6.
34. Gibbs CR, Blann AD, Watson RDS, et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm. Circulation 2001; 103: 1746-51.
35. Dries DL, Exner DV, Gersh BJ. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32: 695-703.
36. Cioffi G, Pozzoli M, Forni G, et al. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J 1996; 17: 1381-9.
37. Chandler WL, Alessi MD, Aillaud MF, et al. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997; 96: 761-8.
38. Conway DSG, Pearce LA, Chin BSP, et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-5.